Albany Molecular Research (AMRI) Enters Multi-Year Supply Agreement with Shire

November 29, 2016 7:46 AM EST

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

AMRI (Nasdaq: AMRI) announced that it has entered into a multi-year supply agreement for an undisclosed product with Shire US Manufacturing, Inc. which product has been in AMRI's portfolio through the required stages of development. Shire plc, is a leading global biotechnology company focused on developing and marketing innovative medicines for patients with rare diseases and other highly specialized conditions. The terms of the agreement are confidential. This is the second such multi-year agreement between AMRI and Shire, as AMRI has also been supplying a key neuroscience product to Shire.

"This agreement builds on the long-standing development and manufacturing relationship between Shire and AMRI," said William S. Marth, President and CEO of AMRI. "This long term contract with Shire illustrates our global and growing integrated API contract manufacturing business well and we look forward to continuing our relationship."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Management Comments

Related Entities


Add Your Comment